Home Infusion for Rheumatoid Arthritis: Remicade, Biologics, and What to Expect

May 30, 2026

Home Infusion for Rheumatoid Arthritis: Remicade, Biologics, and What to Expect

Rheumatoid arthritis (RA) is a chronic autoimmune disease that causes joint inflammation, pain, and progressive damage if not adequately treated. For patients with moderate-to-severe RA who have not responded to conventional disease-modifying drugs (DMARDs), IV biologic therapies, most commonly Remicade (infliximab), are a cornerstone of long-term disease management.


Receiving these infusions through home infusion therapy is an established option for appropriate patients, eliminating the need for repeated trips to an infusion center. Pharmko provides IV biologic therapy for rheumatoid arthritis across 22+ states with full nursing and clinical support.


How IV Biologics Work for Rheumatoid Arthritis


Biologic medications for RA are engineered proteins that target specific components of the immune response driving joint inflammation. Unlike conventional DMARDs (methotrexate, hydroxychloroquine), which suppress the immune system broadly, biologics block precise inflammatory pathways, allowing for more targeted disease control with a different side effect profile.


The most common IV biologics used in rheumatoid arthritis include:


Remicade (infliximab)

Remicade targets tumor necrosis factor-alpha (TNF-α), a key driver of joint inflammation in RA. It is given by IV infusion at weeks 0, 2, and 6 for induction, then every 8 weeks for maintenance. Remicade is often combined with methotrexate to reduce the formation of anti-drug antibodies and improve long-term efficacy.


Orencia (abatacept)


Orencia works differently from TNF inhibitors, it blocks T-cell activation, an earlier step in the inflammatory cascade. It is administered monthly by IV infusion after a loading dose schedule at weeks 0, 2, and 4. Orencia is often preferred for patients who have not responded to or tolerated TNF inhibitors.


Actemra (tocilizumab)


Actemra targets the interleukin-6 (IL-6) receptor, blocking a cytokine that plays a central role in RA inflammation and systemic symptoms including fatigue and anemia of chronic disease. It is given every 4 weeks by IV infusion. Actemra is also used as monotherapy (without methotrexate) in patients who cannot tolerate conventional DMARDs.


Who Qualifies for Home Infusion of IV Biologics for RA?


Home infusion of IV biologics for rheumatoid arthritis is appropriate for patients who:


  • Have received at least their first two to three infusions in a supervised clinical or infusion center setting to screen for infusion reactions
  • Are on a stable, maintenance dose without recent significant reactions
  • Have been assessed by their rheumatologist as clinically stable for home-based administration
  • Have a home environment that supports safe IV administration


Patients who are newly starting a biologic, have a history of serious infusion reactions, or have active infection or significant immunosuppression typically require supervised infusions until their clinical situation is established.


What a Home Biologic Infusion for RA Looks Like


Before the infusion


Your rheumatologist confirms your next infusion is due and submits orders to Pharmko. Our team verifies your insurance coverage, prepares your medication, and schedules a nursing visit. Before the infusion begins, your Pharmko nurse reviews your current medications, checks for signs of active infection, and takes baseline vital signs. Pre-medications (acetaminophen, antihistamine, or corticosteroid) may be given per your rheumatologist's orders.


During the infusion


Infusion duration varies by medication: Remicade typically takes 2 hours, Orencia approximately 30 minutes, and Actemra about 1 hour. Your nurse monitors your vital signs throughout and is present to respond immediately to any reaction. The rate may be slowed if you experience any discomfort.


After the infusion


Your nurse documents the session and communicates with your rheumatologist's office. You will be monitored briefly before the nurse leaves. Know which symptoms should prompt a call in the hours and days after your infusion, delayed reactions can occur with biologics, and our 24/7 after-hours support line is available around the clock.


Managing Infection Risk on IV Biologics


All IV biologics used in RA suppress components of the immune system, which increases susceptibility to infection. Before starting or continuing biologic therapy, your rheumatologist will typically screen for tuberculosis, hepatitis B, and ensure vaccinations are up to date.


During home infusion therapy, contact Pharmko immediately if you develop fever, new respiratory symptoms, skin infections, or any symptoms that seem unusual. Do not wait until your next scheduled infusion. Infection risk is one of the primary reasons biologics require ongoing clinical supervision even when administered at home.


Remicade for RA vs Crohn's Disease


Remicade is FDA-approved for both rheumatoid arthritis and inflammatory bowel disease. While the mechanism is the same, TNF-α inhibition, the dosing, monitoring, and clinical context differ between these indications. For patients managing both RA and GI conditions, or for providers comparing these use cases, our guide on home infusion for Crohn's disease covers the IBD-specific context in detail. A broader overview of IV biologics across autoimmune conditions is available in our article on home infusion for autoimmune diseases.


Insurance Coverage for Home Biologic Infusions


IV biologics for rheumatoid arthritis are typically covered under the medical benefit — not the pharmacy benefit — by Medicare Part B and most commercial insurance plans when administered by a licensed provider. Prior authorization is required and must document clinical indication, prior DMARD history, and current disease activity. Pharmko manages the full authorization process and will communicate any coverage concerns before your first home infusion.


Step therapy requirements, where insurers require trial and failure of less expensive agents before approving a biologic, are common. Pharmko's authorization team is experienced with RA-specific step therapy documentation and can support your rheumatologist in building the necessary clinical record.


Getting Started


If you or your patient is on a stable IV biologic for rheumatoid arthritis and interested in transitioning to home infusion, the first step is a referral from your rheumatologist. Pharmko works with rheumatology practices across 22+ states and can typically initiate therapy within 24–72 hours of referral acceptance.


→ Submit a referral or contact Pharmko: 1-877-540-2003 · info@pharmko.com


Person living with end stage renal disease going about an ordinary morning at home
September 1, 2026
Straight answers to what people on dialysis ask most: nutrition, phosphate, energy, travel, and the emotional weight of ongoing treatment.
Handwritten list of questions prepared for a dialysis appointment about IDPN therapy
September 1, 2026
The questions worth bringing to your nephrologist or dietitian before starting intradialytic parenteral nutrition, grouped and ready to print.
Adult daughter and her mother reviewing a delivery schedule together in the kitchen at home
September 1, 2026
A practical guide for caregivers: what your role is, what the pharmacy can share with you, what to keep track of, and how to protect your own energy.
Family sharing a meal at home while one member on parenteral nutrition joins the table
September 1, 2026
Whether you can eat on parenteral nutrition, why appetite and taste change, and how to handle meals with family while receiving IV nutrition.
Suitcase packed with a small cooler and paperwork for traveling while on parenteral nutrition
August 31, 2026
How to plan a trip on TPN or home parenteral nutrition: supplies, refrigeration, air travel documentation, and how far ahead to call your pharmacy.
Home delivery of TPN supplies unpacked on a kitchen table during the first week of therapy
August 31, 2026
A day-by-day look at starting total parenteral nutrition at home: the first delivery, the first infusion, night one, and when to call for help.
Dialysis center staff coordinating phosphate binder supply with a pharmacy partner
August 11, 2026
What dialysis centers should look for in a phosphate binder supply partner: reliable delivery, formulary breadth, insurance support, and coordination.
Renal dietitian reviewing phosphate levels with a dialysis patient
August 11, 2026
How hyperphosphatemia is managed in ESRD dialysis patients, diet, dialysis, and phosphate binders, and why reliable binder supply keeps therapy on track.
July 29, 2026
Compounded medications are a routine part of modern care, but unlike mass-manufactured drugs, each one is prepared individually, which means the standards behind its preparation carry real weight. For providers who order or refer for compounded therapies, a working understanding of those standards is the clearest way to judge whether a pharmacy is safe to trust. This overview covers the standards that govern sterile compounding and what they mean for the medications your patients receive. Why Standards Matter More in Compounding A commercially manufactured drug is produced under FDA oversight in large, validated batches. A compounded medication is prepared for an individual patient, often in small quantities, sometimes because no commercial equivalent exists. That flexibility is exactly why it's clinically valuable — and why the standards around preparation exist. Without rigorous controls, the same customization that helps patients could introduce contamination or error. Our guide to our sterile compounding pharmacy describes how those controls come together in practice. The Regulatory Landscape Sterile compounding sits within a layered framework: The United States Pharmacopeia (USP) publishes the general chapters, most importantly <797> and <800>, that define how compounded preparations should be made and handled. State boards of pharmacy license and inspect pharmacies, including where they're permitted to ship. Multi-state operations must maintain licensure in each state they serve. Accreditation bodies (ACHC, NABP, PCAB) provide independent verification that a pharmacy meets recognized standards. Together, these create the accountability structure behind every compounded dose. USP <797>: Sterile Preparations USP <797> is the cornerstone standard for compounded sterile preparations. It governs the conditions and practices required to keep a preparation free of contamination, including personnel training and garbing, ISO-classified air quality and engineering controls, environmental monitoring, and beyond-use dating. For any medication infused directly into the body, <797> compliance is the baseline expectation, not a premium feature. USP <800>: Hazardous Drugs USP <800> adds a containment layer for hazardous drugs, protecting personnel, patients, and the environment from unintended exposure. It specifies containment engineering controls, PPE, and validated handling procedures for drugs identified as hazardous. When a preparation is both sterile and hazardous, it must satisfy <797> and <800> together. For the details, see our breakdown of USP <800> requirements . Accreditation: Independent Verification Standards are only meaningful if someone checks that they're being met. Accreditation from ACHC, NABP, and PCAB means a pharmacy has been inspected against national benchmarks by an outside authority. For a provider, accreditation is a shortcut to confidence: it signals that the pharmacy's claims about its processes have been independently validated. The Quality-Control Process Behind the standards is a repeatable process that governs each preparation: Pharmacist review of the prescription for appropriateness, compatibility, and dosing Preparation by trained technicians under aseptic conditions In-process and final verification by a licensed pharmacist Sterility testing or filtration validation where required This chain is what turns a standard on paper into a safe medication in a patient's hands. What This Means When You Order When you refer a patient for a compounded therapy, you're effectively extending your own standard of care into another facility. Knowing that a pharmacy is USP-compliant, accredited, and pharmacist-led lets you refer with confidence that the medication will meet the same expectations you'd hold for anything you administer yourself. If you're weighing options, our guide on how to choose a compounding partner walks through the criteria. The Pharmko Standard Pharmko compounds every TPN, IDPN, and IPN preparation in a USP <797>-compliant, ISO Class 5 cleanroom, under ACHC, NABP, and PCAB accreditation, with a licensed pharmacist reviewing and releasing each formula. For the patients who receive our preparations, many of them managing End Stage Renal Disease (ESRD), that standard is the point. Refer a Patient → · [1 (877) 540-2003]
Physician evaluating a sterile compounding pharmacy partner
July 29, 2026
How to evaluate a sterile compounding pharmacy: accreditation, USP compliance, clinical support, turnaround, and the questions every practice should ask.
Show More